Cryo Cell International (CCEL) EBITDA (2010 - 2026)

Cryo Cell International has disclosed EBITDA across 17 years of filings, most recently posting $765134.0 for Q1 2026.

• In Q1 2026, EBITDA fell 27.54% year-over-year to $765134.0; the TTM figure through Feb 2026 stood at $191517.0 (down 76.75% YoY), while the FY2025 annual figure was $1.4 million, up 99.1% from the prior year.
• EBITDA climbed to $765134.0 in Q1 2026, from -$4.0 million in the prior quarter.
• Over the last five years, EBITDA for CCEL reached as high as $1.9 million in Q3 2025 and fell as low as -$16.2 million in Q4 2023.
• The 5-year median for EBITDA is $1.1 million (2025), against an average of -$574744.6.
• Annual changes were most pronounced in 2023 — EBITDA tumbled 453.57% — and 2024, when it jumped 81.37%.
• A 5-year view of EBITDA shows it stood at -$2.9 million in 2022, then plunged by 453.57% to -$16.2 million in 2023, then jumped by 81.37% to -$3.0 million in 2024, then slumped by 31.62% to -$4.0 million in 2025, then soared by 119.29% to $765134.0 in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $765134.0, -$4.0 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.